Ocular toxicities of MEK inhibitors and other targeted therapies.
about
Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia.Neuro-ophthalmic side effects of molecularly targeted cancer drugs.FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial.New features in MEK retinopathy
P2860
Ocular toxicities of MEK inhibitors and other targeted therapies.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Ocular toxicities of MEK inhibitors and other targeted therapies.
@en
type
label
Ocular toxicities of MEK inhibitors and other targeted therapies.
@en
prefLabel
Ocular toxicities of MEK inhibitors and other targeted therapies.
@en
P2860
P356
P1433
P1476
Ocular toxicities of MEK inhibitors and other targeted therapies
@en
P2093
J P Velazquez-Martin
N Stjepanovic
P2860
P304
P356
10.1093/ANNONC/MDW100
P577
2016-03-06T00:00:00Z